Tobevibart + Elebsiran + Bulevirtide
Phase 3Recruiting 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Viral Hepatitis
Conditions
Viral Hepatitis
Trial Timeline
Jul 30, 2025 โ Jul 1, 2031
NCT ID
NCT07128550About Tobevibart + Elebsiran + Bulevirtide
Tobevibart + Elebsiran + Bulevirtide is a phase 3 stage product being developed by Vir Biotechnology for Viral Hepatitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07128550. Target conditions include Viral Hepatitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07142811 | Phase 2 | Active |
| NCT07128550 | Phase 3 | Recruiting |
Competing Products
17 competing products in Viral Hepatitis